Cerus Corp. (CERS)

5.36
0.05 0.94
NASDAQ : Health Technology
Prev Close 5.31
Open 5.31
Day Low/High 5.29 / 5.42
52 Wk Low/High 1.93 / 5.85
Volume 511.89K
Avg Volume 1.52M
Exchange NASDAQ
Shares Outstanding 129.60M
Market Cap 697.23M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cerus' RedeS Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

Cerus' RedeS Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

Cerus Corporation (NASDAQ: CERS) announced today that Baylor St. Luke's Medical Center in Houston became the first center in the continental U.

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

Cerus Announces The Fourth Biologics License Application (BLA) Approval For A U.S. Blood Center Customer

Cerus Announces The Fourth Biologics License Application (BLA) Approval For A U.S. Blood Center Customer

Cerus Corporation (NASDAQ: CERS) announced today that The Community Blood Center (CBC) of Appleton, Wisconsin received approval by the U.

Cerus Corporation Reports Record Fourth Quarter And Year End 2017 Results

Cerus Corporation Reports Record Fourth Quarter And Year End 2017 Results

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Cerus To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

Cerus To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

Cerus Corporation (NASDAQ: CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care...

Cerus To Release Fourth Quarter And Year End 2017 Results On March 8, 2018

Cerus To Release Fourth Quarter And Year End 2017 Results On March 8, 2018

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2017 will be released on Thursday, March 8, 2018, after the close of the stock market.

Cerus Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriter's Option To Purchase Additional Shares

Cerus Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriter's Option To Purchase Additional Shares

Cerus Corporation (NASDAQ:CERS) today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the...

Cerus Announces Pricing Of Public Offering Of Common Stock

Cerus Announces Pricing Of Public Offering Of Common Stock

Cerus Corporation (NASDAQ:CERS) today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.

Cerus Announces Public Offering Of Common Stock

Cerus Announces Public Offering Of Common Stock

Cerus Corporation (NASDAQ: CERS) today announced that it has commenced a registered underwritten public offering of $50.

Cerus Reports Positive Top-Line Results From Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells In Thalassemia Patients

Cerus Reports Positive Top-Line Results From Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells In Thalassemia Patients

Cerus Corporation (NASDAQ: CERS) today reported that the primary efficacy and safety endpoints were successfully achieved in the company's Phase 3 transfusion study of chronic anemia evaluating INTERCEPT-treated red blood...

Commit To Purchase Cerus Corp. At $3, Earn 10% Using Options

Commit To Purchase Cerus Corp. At $3, Earn 10% Using Options

Investors eyeing a purchase of Cerus Corp. stock, but cautious about paying the going market price of $4.22/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Cerus Corporation Announces Preliminary Product Revenue Results For Fourth Quarter And Full Year 2017

Cerus Corporation Announces Preliminary Product Revenue Results For Fourth Quarter And Full Year 2017

Cerus Corporation (NASDAQ: CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2017 and provided 2018 product revenue guidance.

Cerus Corporation Receives IDE Approval To Initiate Phase III ReCePI Study

Cerus Corporation Receives IDE Approval To Initiate Phase III ReCePI Study

Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.

Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2017.

Cerus To Present At Two Upcoming Conferences

Cerus To Present At Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that management will present at two upcoming investor conferences: Stephens Fall Investor Conference at the Lotte New York Palace Hotel in New York City on...

Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy

Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy.

Cerus Announces Agreement With Transfusion Center Of The Community Of Madrid

Cerus Announces Agreement With Transfusion Center Of The Community Of Madrid

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a supply agreement with Centro de Transfusión de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.

Cerus Announces National German Reimbursement For Pathogen Inactivated Platelets

Cerus Announces National German Reimbursement For Pathogen Inactivated Platelets

Cerus Corporation (NASDAQ:CERS) announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets...

Cerus To Release Third Quarter 2017 Results On November 2, 2017

Cerus To Release Third Quarter 2017 Results On November 2, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market.

Cerus Announces First Biologics License Application Approval For U.S. Blood Center Customer

Cerus Announces First Biologics License Application Approval For U.S. Blood Center Customer

Cerus Corporation (NASDAQ:CERS) announced today that Rhode Island Blood Center received approval by the U.

Cerus Announces Schedule Of Presentations At The 2017 AABB Annual Meeting

Cerus Announces Schedule Of Presentations At The 2017 AABB Annual Meeting

Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events at the AABB (formerly known as the American Association of Blood Banks) Annual Meeting to be held October 7-10 in San Diego, California.

Cerus To Present At Cantor Fitzgerald's Annual Healthcare Conference On September 27, 2017

Cerus To Present At Cantor Fitzgerald's Annual Healthcare Conference On September 27, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 10:20...

Cerus To Present At Two Upcoming Conferences

Cerus To Present At Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, will present at two upcoming conferences: Baird's 2017 Global Healthcare Conference...

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2017.

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and...

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System.

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Corporation (NASDAQ:CERS) announced today an agreement with the Central California Blood Center (CCBC) in which CCBC will manufacture pathogen-reduced cryoprecipitate ("cryo") for the company.

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter results will be released on Thursday, August 3, 2017, after the close of the stock market.

TheStreet Quant Rating: D- (Sell)